Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

CHESTERBROOK, Pa., Dec.  23, 2019  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist. TRV734 is currently being evaluated as a potential maintenance therapy for opioid use disorder.

Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder

Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option

Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting

Trevena: Don't Get Hooked On This One

Safety and tolerability demonstrated in diverse patient populations and surgeries

Trevena Announces Publication of Results from Phase 3 “Real World” Safety Study for Oliceridine in The Journal of Pain Research

No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment

Trevena Announces Publication of Results from Special Population Studies for Oliceridine

CHESTERBROOK, Pa., Nov.  18, 2019  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel, to be held at the Lotte New York Palace Hotel in New York City on Wednesday, November 20, 2019 at 8:35 a.m. EST.

Trevena to Present at the Stifel 2019 Healthcare Conference

CHESTERBROOK, Pa., Oct.  21, 2019  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) conditions, today announced four presentations at ANESTHESIOLOGY® 2019, the national conference for the American Society of Anesthesiologists, held at the Orange County Convention Center in Orlando, Florida, October 19-23.  The presentations included one oral presentation and three posters, all of which discussed the safety profile of oliceridine.

Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting

CHESTERBROOK, Pa., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will present at the 2019 Cantor Global Healthcare Conference sponsored by Cantor Fitzgerald, to be held at the InterContinental New York Barclay Hotel in New York City on Friday, October 4, 2019 at 8:20 a.m. EST.

Trevena to Present at the 2019 Cantor Global Healthcare Conference

Trevena has been struggling lately, but the selling pressure may be coming to an end soon.

Trevena Sees Hammer Chart Pattern: Time to Buy?

CHESTERBROOK, Pa., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will participate in two upcoming conferences:

Trevena to Participate in Upcoming Conferences in September 2019

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q2 2019 Results - Earnings Call Transcript

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2019 Results - Earnings Call Transcript

During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

In my most recent article FDA Minutes To Bring Trevena Back To Life, I discussed how the release of the minutes from the FDA meeting could potentially relaunch Trevena into the public arena as a viable candidate to be next in line for an FDA approval and the recipient of potential M&A activity.

Trevena Brings Clarity To Investors

Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.

Trevena (TRVN) Gains As Market Dips: What You Should Know

Trevena (NASDAQ:TRVN) -12.7% after-hours on disclosing that the FDA rescinded its breakthrough designation on the oliceridine pain management drug after data was not sufficient to support the designation.

Trevena -13% after FDA rescinds breakthrough designation for pain drug

News for Trevena Stock (TRVN)